Wedbush Comments on Geron's FY2029 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN - Free Report) - Investment analysts at Wedbush issued their FY2029 earnings estimates for shares of Geron in a research note issued to investors on Monday, April 21st. Wedbush analyst R. Driscoll anticipates that the biopharmaceutical company will earn $0.96 per share for the year. The consensus estimate for Geron's current full-year earnings is ($0.25) per share.

GERN has been the topic of several other research reports. HC Wainwright reiterated a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. Scotiabank decreased their price objective on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and issued a $5.00 target price on shares of Geron in a research note on Wednesday, March 12th. Stifel Nicolaus reduced their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Finally, B. Riley lowered Geron from a "buy" rating to a "neutral" rating and reduced their target price for the company from $3.50 to $2.00 in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Geron presently has an average rating of "Moderate Buy" and an average target price of $5.75.

Geron Trading Down 1.1 %

Shares of Geron stock traded down $0.02 on Wednesday, hitting $1.41. The stock had a trading volume of 3,038,793 shares, compared to its average volume of 11,473,278. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a twelve month low of $1.17 and a twelve month high of $5.34. The firm has a market capitalization of $894.86 million, a P/E ratio of -4.39 and a beta of 0.66. The stock has a 50 day moving average of $1.64 and a 200 day moving average of $2.91.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). The business had revenue of $47.54 million during the quarter, compared to analysts' expectations of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%.

Institutional Trading of Geron

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Geron during the fourth quarter worth about $28,000. Integrated Wealth Concepts LLC acquired a new position in shares of Geron during the 4th quarter worth approximately $36,000. Sowell Financial Services LLC acquired a new stake in Geron during the first quarter worth $43,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron during the 4th quarter worth approximately $45,000. Finally, 111 Capital purchased a new position in Geron in the fourth quarter valued at $52,000. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.